Section
Setmelanotide, an MC4R agonist, improves metabolic parameters and reduces metabolic syndrome severity in patients with POMC or LEPR deficiencies causing severe obesity, after one year of treatment.
The CONNECT trial demonstrates that continuous glucose monitoring (CGM) significantly improves glycemic control in adults with non-insulin-treated type 2 diabetes managed in primary care, reducing HbA1c levels and hyperglycemia risk without
This study reveals significant hippocampal subfield volume reductions and white matter impairments in patients with congenital adrenal hyperplasia, highlighting sex-specific differences that could influence cognitive outcomes and treatment
This nationwide study examines visual and anatomical responses to anti-VEGF retreatment in diabetic macular edema patients who returned with stabilized vision after being lost to follow-up, highlighting suboptimal gains and implications for
This retrospective study demonstrates that radiofrequency ablation (RFA) effectively treats low-risk papillary thyroid microcarcinomas (PTMC), including those with intratumoral calcifications, with excellent technical success, significant t
A comprehensive review of the ACHIEVE-4 trial confirms orforglipron’s cardiovascular safety non-inferior to insulin glargine in type 2 diabetes patients at elevated cardiovascular risk, highlighting its oral administration and safety
This study reveals that elevated 12,13-diHOME levels, reflecting brown adipose tissue activation during targeted temperature management after cardiac arrest, correlate with improved survival and distinct immunometabolic profiles.
Saroglitazar significantly improves liver fat content, liver enzymes, and lipid profiles in women with PCOS and MASLD, highlighting its potential as a therapeutic option in this underrepresented population.
Recent advances in diabetes care have reduced mortality risk in type 1 diabetes, yet females with type 1 diabetes continue to experience disproportionately higher relative mortality compared to males.
This Phase II trial demonstrates that HRS-7535, an oral small-molecule GLP-1 receptor agonist, significantly improves glycaemic control and is well-tolerated in type 2 diabetes patients inadequately controlled with metformin and SGLT2 inhib
This review synthesizes evidence on GLP-1 receptor agonist initiation impacting psychiatric hospitalisation and emergency visits in adults with schizophrenia and type 2 diabetes, highlighting metabolic and psychiatric interplay and therapeu
This review synthesizes evidence from large cohort studies and meta-analyses highlighting bariatric surgery’s association with reduced risks of many obesity-related cancers, consistent across age and sex. Mechanistic insights and impl
This study finds that waist circumference is a better and more practical tool than traditional cardiometabolic indices for detecting hypogonadism in men with Klinefelter Syndrome, enhancing clinical assessment beyond age alone.
GLP-1 receptor agonists exhibit promising osteoprotective and anti-inflammatory effects in preclinical dental studies but lack robust clinical data, underscoring urgent research needs on their oral health impact and safety profile.
A large cohort study reveals that patients with mild autonomous cortisol secretion (MACS) in adrenal tumors are at increased risk for psychiatric disorders, highlighting the need for integrated psychiatric assessment in this population.
Survodutide, a dual glucagon and GLP-1 receptor agonist, demonstrates significant weight loss and glycemic improvements in adults with obesity and type 2 diabetes, offering promise as a novel therapeutic agent with favorable efficacy and sa
This study reveals how diabetes and ASCVD alter the link between soluble TNF receptor 1 levels and 90-day sepsis mortality, informing biomarker-guided risk assessment and understanding of sepsis pathobiology.
More than one-third of Hispanic/Latino adults with diabetes exhibit diabetic retinopathy (DR), with significant variability across backgrounds. Hypertension notably associates with DR and vision-threatening DR, highlighting the need for tar
The twiist AID system significantly improves glycemic control and patient satisfaction in insulin-treated type 2 diabetes over 13 weeks, demonstrating safety and effectiveness supported by complementary real-world and RCT data.
Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, significantly reduces bodyweight and improves glycemic control in adults with obesity and type 2 diabetes, showing promising efficacy and a manageable safety profil
